Author:
Mlugu Eulambius M.,Minzi Omary M.S.,Johansson Mats,Kamuhabwa Appolinary A. R.,Aklillu Eleni
Abstract
Abstract
Background
Dihydroartemisinin-piperaquine (DHP) recently showed superior effectiveness over sulfadoxine-pyrimethamine for malaria intermittent preventive treatment in pregnancy (IPTp). We investigated day 7 piperaquine pharmacokinetics and its therapeutic efficacy in preventing malaria during pregnancy.
Methods
Malaria-free (mRDT) pregnant women (n = 400) who received monthly IPTp-DHP were enrolled and followed till delivery. Day 7 Plasma piperaquine concentrations were determined after each IPTp dose using UPLC/MS/MS. IPTp outcomes (symptomatic malaria and parasitemia during pregnancy, placental malaria, and maternal malaria at delivery) were monitored. Linear mixed model and Cox regression were used to assess predictors of day 7 piperaquine concentration and treatment outcome, respectively.
Results
The incidences of symptomatic malaria and parasitemia during pregnancy per 100 person-year at risk were 2 and 33, respectively. The prevalence of histopathologically confirmed placental malaria and maternal malaria at delivery were 3% and 9.8%, respectively. Repeated monthly IPTp-DHP resulted in significantly increased day 7 plasma piperaquine concentration (p < 0.001). Following the 1st, 2nd, and 3rd monthly IPTp-DHP doses, the proportions of women with day 7 piperaquine concentration below the therapeutic threshold (< 30 ng/mL) were 6.1%, 4.1% and 3.6%, respectively. Factors such as maternal age, body weight and trimester were not significant predictors of day 7 piperaquine concentration. However, having a low day 7 piperaquine plasma concentration (< 30 ng/mL) was significantly associated with a higher risk of parasitemia during pregnancy (p = 0.004).
Conclusion
Lower day 7 piperaquine plasma concentration is a risk factor for parasitemia during pregnancy. Single plasma sampling at day 7 can be used to monitor piperaquine effectiveness during IPTp-DHP.
Trial registration
Registered 09/12/2016, PACTR201612001901313.
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. WHO. World Malaria Report 2023. Geneva: World Health Organization; 2023. Licence: CC BY-NC-SA 3.0 IGO. https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2023 [Accessed on 18 Jan 2024].
2. WHO. A strategic framework for malaria prevention and control during pregnancy in the african region (2004). https://www.afro.who.int/sites/default/files/2017-06/malaria_in_pregnancy_092004.pdf [Accessed on 12 Apr 2023]. 2004
3. Bwire GM, Mikomangwa WP, Kilonzi M. Occurrence of septuple and elevated pfdhfr-pfdhps quintuple mutations in a general population threatens the use of sulfadoxine-pyrimethamine for malaria prevention during pregnancy in eastern-coast of Tanzania. BMC Infect Dis. 2020;20:530.
4. Baraka V, Ishengoma DS, Fransis F, Minja DTR, Madebe RA, Ngatunga D, Van Geertruyden J-P. High-level Plasmodium Falciparum sulfadoxine-pyrimethamine resistance with the concomitant occurrence of septuple haplotype in Tanzania. Malar J. 2015;14:439–439.
5. Desai M, Gutman J, L’Lanziva A, Otieno K, Juma E, Kariuki S, Ouma P, Were V, Laserson K, Katana A, et al. Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial. Lancet. 2015;386:2507–19.